CTLA4 and neoplasm: Even when using CTLA-4 and PD-L1 inhibitors, immunosuppressive cells in the tumor microenvironment (such as MDSCs and Tregs) can hinder T-cell activity by secreting immunosuppressive factors like TGF-β and IL-10, allowing tumors to evade immune attack (45).